S&P 500, Nasdaq, Dow, FTSE, Nikkei and global benchmarks.
Moderna will enter the Nasdaq-100 on Oct 9 after a 175% third-quarter rally powered by the first-ever Phase 3 win for a personalized mRNA cancer vaccine — forcing $800B+ in index funds to buy in.
India's Nifty 50 has declined for eight consecutive weeks, its longest losing run in 25 years, erasing Rs 28.3 lakh crore in investor wealth and pushing the index within sight of a bear market.
S&P 500 futures climbed out of their August-September downtrend channel and are now testing a shorter descending trendline near 7,810, after a soft September jobs report cut October Fed hike odds to about 23%.
Pakistan's KSE-100 closed Friday at 168,155, down 481 points, as US-Iran tensions and elevated crude kept buyers away despite a late slide in oil prices.
The Sensex fell 2.27% over five sessions ended October 1 as a broad selloff swept India's midcaps: 14 BSE MidCap stocks dropped more than 5%, with PB Fintech sliding 19%.
The S&P 500 gave up 0.27% in the first trading week of October as healthcare and financial shares sank, while tech strength and a soft jobs report kept the Nasdaq on a record run.
September's jobs report showed just 29,000 new jobs against 90,000 expected, sending the Nasdaq to a record 27,191 as traders cut October Fed hike odds to 21%.
The FTSE 100 bounced back from a four-day losing streak as Brent crude slipped to $99.90 and softer bond yields lifted London equities, with miners and JD Wetherspoon leading the advance.
The Hang Seng slid as much as 3% — its biggest drop since March — leading Asian losses as surging US yields and China stimulus disappointment hit financials.
